AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$SYRE

Burrows Scott L sold $184K of SYRE

Burrows Scott L (Chief Financial Officer) sold 2,599 shares of Spyre Therapeutics, Inc. (SYRE) at $70.77 ($0.18M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burrows Scott L
Published Jun 4, 2026, 1:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$SYRE
Neutral
medium confidence
Mentioned
$SYRE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYRENeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not introduce new company-specific fundamentals (no earnings, trial, deal, or regulatory action mentioned).

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure generally limits immediate trading signal strength.

03

What to watch

The filing does not disclose reasons for sale; traders should avoid over-interpreting 10b5-1 transactions as bearish fundamentals.

Relevance 6/10Novelty 3/10Timing: Filed June 3; sale executed June 1 (10b5-1 open-market).

Background

This is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics (SYRE).

Company-level read

Ticker impact

$SYRENeutralMedium confidence
Context

Spyre Therapeutics CFO Burrows Scott L sold $183,931 of SYRE shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Near-term impact likely muted; any reaction may be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a routine insider sale with stated 10b5-1 plan, which typically reduces interpretive weight versus unscheduled selling.

Market effects

Sector

Minimal—single-company insider transaction with no stated operational/regulatory catalyst.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is pre-arranged, it could be mechanically timed around liquidity needs without reflecting negative outlook.

Key entities

  • issuer
    Spyre Therapeutics, Inc.

    SYRE, subject of the Form 4 insider sale by its CFO.

  • insider
    Burrows Scott L

    CFO who sold 2,599 SYRE shares at $70.7700 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 4
$SYREMed

Spyre Therapeutics, Inc. (SYRE): Results of Operations and Financial Condition

Spyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 spyre-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), d

SEC EDGAR 8-K6 min
JUN 26
$SYREMed

Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)

Spyre Therapeutics (NASDAQ:SYRE) shares fell 13.7% in premarket trading after SEC Form 4 filings showed major insider-related sales. Fairmount Healthcare Fund II L.P., affiliated with Spyre directors, sold 4,684,781 common shares on June 23 for about $399.7 million, leaving zero common shares. Spyre director Michael Thomas Henderson sold 20,000 shares for about $2 million under a Rule 10b5-1 plan.

finance.yahoo.com4 min